Vadim Koshkin, MD, UCSF, San Francisco, CA, discusses a Phase II trial (NCT04601857) of first-line combination of futibatinib and pembrolizumab in patients with platinum-ineligible metastatic urothelial carcinoma (mUC), with or without FGFR alterations. The combination demonstrated durable responses, particularly in patients with FGFR3 mutations or FGFR1–4 rearrangements. A manageable safety profile, including common adverse events such as hyperphosphatemia and diarrhea, was also reported. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
